Medicare Part D drugs starting with N
102 drugs start with N; 43 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Nubeqa in 2024: $998 million, what plans and patients paid at the pharmacy before rebates.
Which drugs start with N?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Nabumetone | 99.3% | Tier 2 | $10 million |
| Nadolol | 91.5% | Tier 2 | $15 million |
| Nafcillin | 99.1% | Tier 4 | $3 million |
| Naftifine hydrochloride | 14.1% | Tier 4 | $4 million |
| Naloxone / pentazocine | 2% | Tier 2 | $735 thousand |
| Naloxone hydrochloride | 100% | Tier 2 | $45 million |
| Naltrexone hydrochloride | 100% | Tier 2 | $23 million |
| Namzaric (donepezil hydrochloride / memantine hydrochloride) | 38.8% | Tier 4 | $90 million |
| Naproxen | 100% | Tier 1 | $36 million |
| Naproxen sodium | 72.6% | Tier 2 | $6 million |
| Naproxen sodium / sumatriptan | 1.2% | Tier 4 | $2 million |
| Naratriptan | 94.8% | Tier 2 | $3 million |
| Nardil (phenelzine) | 0.2% | Tier 1 | $107 thousand |
| Natacyn (natamycin) | 94.2% | Tier 4 | $970 thousand |
| Natazia (dienogest / estradiol valerate) | 14.9% | Tier 4 | $99 thousand |
| Nateglinide | 99.5% | Tier 1 | $8 million |
| Nayzilam (midazolam) | 100% | Tier 4 | $37 million |
| Nebivolol | 96.9% | Tier 2 | $80 million |
| NebuPent (pentamidine isethionate) | 1.5% | Tier 1 | no 2024 match |
| Necon (ethinyl estradiol / norethindrone) | 86.4% | Tier 2 | $9 thousand |
| Nefazodone hydrochloride | 100% | Tier 4 | $1 million |
| Neffy (epinephrine) | 1% | Tier 4 | $210 thousand |
| Nemluvio (nemolizumab-ilto) | 6.9% | Tier 5 | $14 million |
| Neo-Synalar (fluocinolone acetonide / neomycin sulfate) | 0.8% | Tier 4 | $277 thousand |
| Neomycin sulfate | 100% | Tier 2 | $954 thousand |
| Neoral (cyclosporine, modified) | 2.4% | Tier 4 | $925 thousand |
| Nerlynx (neratinib) | 100% | Tier 5 | $38 million |
| Neuac (benzoyl peroxide / clindamycin phosphate) | 31.4% | Tier 3 | $772 |
| Neulasta (pegfilgrastim) | 26.8% | Tier 5 | $53 million |
| Neupogen (filgrastim) | 5.3% | Tier 5 | $7 million |
| Neupro (rotigotine) | 33.9% | Tier 4 | $90 million |
| Neurontin (gabapentin) | under 0.1% | Tier 1 | $19 million |
| Nevanac (nepafenac) | 0.4% | Tier 3 | $2 million |
| Nevirapine | 100% | Tier 2 | $2 million |
| Nexavar (sorafenib) | 0.2% | Tier 1 | $4 million |
| Nexium (esomeprazole) | under 0.1% | Tier 1 | $60 million |
| Nexletol (bempedoic acid) | 93.4% | Tier 3 | $71 million |
| Nexlizet (bempedoic acid / ezetimibe) | 84.4% | Tier 3 | $71 million |
| Nexplanon (etonogestrel) | 100% | Tier 3 | $455 thousand |
| Nextstellis (drospirenone / estetrol) | under 0.1% | Tier 2 | $94 thousand |
Show the other 62 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Ngenla (somatrogon-ghla) | 0.4% | Tier 5 | no 2024 match |
| Niacin | 98.7% | Tier 2 | $13 million |
| Niacor (niacin) | 54.6% | Tier 4 | $103 thousand |
| Nicardipine hydrochloride | 60.9% | Tier 4 | $3 million |
| Nicotrol (nicotine) | 100% | Tier 4 | $740 thousand |
| Nifedipine | 99.3% | Tier 2 | $100 million |
| Nikki (drospirenone / ethinyl estradiol) | 93.3% | Tier 2 | $129 thousand |
| Nilotinib | 99.4% | Tier 5 | no 2024 match |
| Nilotinib d-tartrate | 37.7% | Tier 5 | no 2024 match |
| Nilutamide | 100% | Tier 5 | $1 million |
| Nimodipine | 82.9% | Tier 4 | $797 thousand |
| Ninlaro (ixazomib) | 100% | Tier 5 | $273 million |
| Nisoldipine | 27.6% | Tier 4 | $4 million |
| Nitazoxanide | 100% | Tier 5 | $4 million |
| Nitisinone | 95.2% | Tier 5 | $443 thousand |
| Nitro-Bid (nitroglycerin) | 71.1% | Tier 4 | $1 million |
| Nitro-Dur (nitroglycerin) | 3.2% | Tier 4 | $3 million |
| Nitrofurantoin | 5.3% | Tier 1 | $26 million |
| Nitrofurantoin, macrocrystals | 99.2% | Tier 3 | no 2024 match |
| Nitrofurantoin, macrocrystals / nitrofurantoin, monohydrate | 100% | Tier 3 | no 2024 match |
| Nitroglycerin | 100% | Tier 2 | $35 million |
| Nitrolingual (nitroglycerin) | 0.3% | Tier 3 | $27 thousand |
| Nitrostat (nitroglycerin) | 2.8% | Tier 3 | $175 thousand |
| Nityr (nitisinone) | 2.8% | Tier 5 | $41 thousand |
| Nivestym (filgrastim-aafi) | 48.7% | Tier 5 | $15 million |
| Nizatidine | 76.3% | Tier 4 | $417 thousand |
| Nora-BE (norethindrone) | 92.4% | Tier 2 | $38 thousand |
| Norditropin (somatropin) | 16.5% | Tier 5 | $16 million |
| Norethindrone | 99.7% | Tier 2 | $1 million |
| Norethindrone acetate | 99.8% | Tier 2 | $2 million |
| Noritate (metronidazole) | 12.6% | Tier 5 | $3 million |
| Norpace (disopyramide) | 15.6% | Tier 4 | $1 million |
| Norpramin (desipramine hydrochloride) | under 0.1% | Tier 1 | no 2024 match |
| Northera (droxidopa) | under 0.1% | Tier 1 | $19 million |
| Nortrel (ethinyl estradiol / norethindrone) | 96.8% | Tier 2 | $400 thousand |
| Nortriptyline | 100% | Tier 2 | $20 million |
| Norvasc (amlodipine) | under 0.1% | Tier 1 | $14 million |
| Norvir (ritonavir) | 100% | Tier 4 | $566 thousand |
| Nourianz (istradefylline) | 3.2% | Tier 5 | $51 million |
| Novolin (insulin isophane, human / insulin, regular, human) | 77.7% | Tier 3 | $48 million |
| Novolin N (insulin isophane, human) | 77.6% | Tier 3 | $21 million |
| Novolin R (insulin, regular, human) | 99.9% | Tier 3 | $17 million |
| NovoLog (insulin aspart, human) | 100% | Tier 3 | $407 million |
| NovoLog Mix (insulin aspart protamine, human / insulin aspart, human) | 78.2% | Tier 3 | $78 million |
| Noxafil (posaconazole) | 2.4% | Tier 5 | $632 thousand |
| Nubeqa (darolutamide) | 100% | Tier 5 | $998 million |
| Nucala (mepolizumab) | 48.8% | Tier 5 | $318 million |
| Nucynta (tapentadol) | 1.5% | Tier 4 | $104 million |
| Nuedexta (dextromethorphan hydrobromide / quinidine sulfate) | 96.4% | Tier 5 | $173 million |
| Nuplazid (pimavanserin) | 100% | Tier 5 | $658 million |
| Nurtec (rimegepant) | 80.6% | Tier 3 | $625 million |
| Nutrilipid (soybean oil) | 75.7% | Tier 4 | no 2024 match |
| NuvaRing (ethinyl estradiol / etonogestrel) | 0.1% | Tier 1 | $168 thousand |
| Nuvigil (armodafinil) | under 0.1% | Tier 1 | $3 million |
| Nuzyra (omadacycline) | 54.7% | Tier 5 | $107 million |
| Nyamyc (nystatin) | 97.2% | Tier 2 | $10 million |
| Nylia (ethinyl estradiol / norethindrone) | 88.6% | Tier 2 | $35 thousand |
| Nymalize (nimodipine) | 0.8% | Tier 5 | no 2024 match |
| Nystatin | 100% | Tier 2 | $53 million |
| Nystatin / triamcinolone acetonide | 48.6% | Tier 2 | $7 million |
| Nystop (nystatin) | 99.4% | Tier 2 | $11 million |
| Nyvepria (pegfilgrastim-apgf) | 20.1% | Tier 5 | $10 million |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans